This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Trendlines Group Announces Co-development Agreement With Endo

TEL AVIV, Israel, November 13, 2012 /PRNewswire/ --

The Trendlines Group today announced it has entered into an R&D agreement aimed at co-developing novel medical devices and technologies within the areas of pain and urology, a strategic focus  of U.S.-based Endo Health Solutions Inc. (Nasdaq: ENDP).  

The work will be conducted by Trendlines Labs, the technology development arm of The Trendlines Group.  Trendlines Labs is co-located with the Misgav Venture Accelerator - The Trendlines Group's incubator focused exclusively on the development of medtech innovations.  Misgav was named "Best Incubator" by Israel's Office of the Chief Scientist of the Ministry of Industry, Trade and Labor in 2010. Trendlines portfolio company Stimatix ( http://www.stimatix-gi.com) was named Israel's best start-up in 2012.

D. Todd Dollinger, Chairman and CEO of Trendlines, stated, "Our work with Endo furthers our market reach and is instrumental to our achieving our mission of creating and developing businesses to improve the human condition."  

Dr. Sujat Sukthankar, Vice President, Device R&D, at Endo said, "The Trendlines-Endo agreement is in line with our stated vision of sourcing innovation globally.  This partnership complements and bolsters our own internal innovation and product development efforts in the areas of pain and urology.  Through this partnership, we are excited to participate in the vibrant medical technology community in Israel. "  

Endo Health Solutions Inc. ( http://www.endo.com) is a U.S.-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through its operating companies: Endo Pharmaceuticals, Qualitest, AMS and HealthTronics, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike.

About The Trendlines Group

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs